Osteogenesis imperfecta is a heritable disorder of bone formation resulting in low bone mass and a propensity to fracture. It exhibits a broad range of clinical severity, ranging from multiple fracturing in utero and perinatal death to normal adult stature and a low fracture incidence. The disorder is currently classified into seven types based on differences in clinical presentation and bone architecture. Mutation in one of the type I collagen genes is commonly associated with osteogenesis imperfecta, but is not a prerequisite for the diagnosis. Indeed, the newer forms of osteogenesis imperfecta (types V, VI and VII) are not associated with type I collagen gene defects. Amongst the type I collagen gene mutations that can occur, missense base substitutions involving glycine codons in the exons encoding the central triple-helix forming domain predominate. Such mutations can occur in all the classical forms of osteogenesis imperfecta (types I-IV), but genotype/phenotype correlations are complex and often unpredictable. Treatment of osteogenesis imperfecta by bisphosphonate therapy can improve bone mass in all types of the disorder, and while not being a cure for the disorder does improve the quality of life of the patient.
Introduction
Osteogenesis imperfecta (OI) is a heritable disorder of bone formation that may affect more than 1:10,000 individuals. It is characterised by bone fragility due to low bone mass giving an increased fracture incidence (Kocher and Shaprio, 1998; Primorac et al., 2001) . The bone fragility has led to the adoption of the trivial name of "brittle bone disease". The heritable nature of the disorder distinguishes it from idiopathic juvenile osteoporosis, although clinical osteoporosis is also a consequence of OI. Patients with OI do not have perturbations in serum calcium and vitamin D metabolite levels as a consequence of their disease, which distinguishes OI from osteomalacia.
Patients with OI may present with other clinical features, but these are by no means universal. Such features include the presence of blue sclera, dentinogenesis imperfecta, skin hyperlaxity and joint hypermobility. These are all features that one might expect to be associated with a disorder involving type I collagen, though such a relationship is not absolute. While individuals with OI having blue sclera and dentinogenesis imperfecta commonly have mutations in one of their type I collagen genes, there are many patients with type I collagen gene mutations who do not exhibit these secondary characteristics. In addition, the OI patient may present with Wormian bones in the sutures of the skull, and may be of decreased height and have skeletal deformity.
OI has been recognised as a disease entity since the 17th century, when it was termed congenital osteomalacia. The term osteogenesis imperfecta was adopted in the late 19th century, and by the start of the 20th century the disorder had been subclassified into congenita and tarda forms to reflect the severe or mild disease that may be present in the young juvenile. As more patients with OI were investigated, the broad clinical spectrum of the disease was more fully recognised and more comprehensive classification systems were adopted. The system in common use today was presented by Sillence et al. (1979) and subdivides patients into four types based on disease severity and progression. However, it is appreciated that in reality the disorder represents a continuum of severity and that patients do not always fall conveniently into one clinical category. The application of modern bone histology techniques has also revealed that individuals with similar clinical presentation may exhibit vastly different changes in their bone architecture. This has led to further subdivisions of the disorder, with seven subtypes now having been defined.
One feature that is apparent from the preceding para-graph is that OI has never been defined using gene mutation as a criterion. Yet there has been a tendency in the past decade to try to redefine OI as a type I collagenopathy (Byers and Steiner, 1992; Prockop et al., 1993) . This would imply that most if not all OI must arise from a mutation in either of the two genes for type I collagen. This is not the case, and while the majority of OI may arise from mutations in these genes there are a considerable number of individuals in whom such mutations are absent and mutation in a different gene is the causative event (Aitchison et al., 1988; Labuda et al., 2002; Wallis et al., 1993) . A priori there is no reason why mutation in different genes cannot give rise to the same clinical phenotype, and therefore the definition of OI should remain a clinical one. However, it is certainly possible that in the future genetic diversity may result in a further subdivision of the disease classification.
Clinical Diversity
The classification system of Sillence et al. (1979) divides OI into four severity-based types, with the type IV category representing the clinically most diverse group. Prior to the analysis of bone architecture, the newer forms of OI (types V-VII) would all have fallen into the type IV category based on clinical presentation alone (Table 1) .
Type I OI
Type I OI is the mildest form of the disease, being nondeforming and resulting in patients attaining a normal height. The patients typically have blue sclera, but dentinogenesis imperfecta is less common. Fractures are not commonly observed at birth, but begin with ambulation and subsequent falls during juvenile development, then commonly decrease following puberty.
Type II OI
Type II OI is the most severe form of the disease resulting in death in the perinatal period, with patients rarely surviving for more than a few days. The individuals exhibit multiple intrauterine rib and long bone fractures, and show severe skeletal deformity. Bone histology reveals a marked decrease in both cortical bone thickness and trabecular bone.
Type III OI
Type III OI is the most severe form of the disease compatible with survival past the perinatal period. It is characterised by severe progressive skeletal deformity that may have begun by birth. Individuals may possess multiple fractures at birth and suffer frequent fractures thereafter because of the highly fragile nature of their bones. The incidence of fracture remains high even in adult life. Individuals have severely short stature and because of their deformity and bone fragility are frequently confined to a wheelchair for life. Dentinogenesis imperfecta is commonly present.
Type IV OI
Type IV OI is clinically the most diverse group in the Sillence classification and encompasses all those individuals who do not meet the criteria for types I-III OI. The phenotype can vary from severe to mild, with the more severely affected patients presenting with fractures at birth, suffering moderate skeletal deformity and attaining a relatively short stature. Because of the phenotypic variability in this group, one might predict it to be the most likely source for genetic heterogeneity.
Type V OI
Type V OI is moderately deforming, and patients exhibit moderate to severe bone fragility . Blue sclera and dentinogenesis imperfecta are not present. The patients are characterised by three distinctive features: the presence of hypertrophic callus formation at fracture sites, calcification of the interosseous membranes between the bones of the forearm, and the presence of a radio-opaque metaphyseal band immediately adjacent to the growth plates upon X-ray. Upon histological examination, the lamellar organisation of the bone has an irregular mesh-like appearance distinct from the normal lamellar organisation (Figure 1 ).
Type VI OI
Type VI OI patients also present with moderate to severe skeletal deformity and do not present with blue sclera or dentinogenesis imperfecta. The distinctive features of this OI type are the fish scale-like appearance of the bone lamellae and the presence of excessive osteoid upon histological examination (Figure 1 ). Although the osteoid accumulation suggests a mineralisation defect reminiscent of osteomalacia, there is no abnormality in calcium, phosphate, parathyroid hormone or vitamin D metabolism, and growth plate mineralisation proceeds normally.
Type VII OI
Type VII OI patients also have moderate to severe skeletal deformity and bone fragility, and lack blue sclera and Osteogenesis imperfecta dentinogenesis imperfecta. The distinctive clinical feature of the disease is a rhizomelic shortening of the humerus and femur . Unlike other forms of OI, which can be inherited in an autosomal dominant manner, type VII OI exhibits autosomal recessive inheritance.
Genetic Diversity
Types I-IV OI are commonly associated with mutations in the genes for type I collagen, whereas to date no type I collagen gene mutation has been detected in types V-VII OI (Table 2 ). In the case of type VII OI, the existence of extended affected families has enabled the chromosome location of the gene defect to be mapped to chromosome 3p22-24.1 (Labuda et al., 2002) . This locus is on a different chromosome from the type I collagen genes, and to date no plausible candidate gene has been identified in this region.
Analysis of type I collagen gene mutations
Owing to the large number of exons in the type I collagen genes, screening techniques have been employed to identify regions of the genes in which a mutation is present and so minimise the amount of nucleotide sequencing required (Nollau and Wagener, 1997; Prosser, 1993) . A variety of different mutation screening techniques have been employed, including chemical cleavage of mismatches (CCM) (Bateman et al., 1993) and conformation sensitive gel electrophoresis (CSGE) (Ganguly et al., 1993; Korkko et al., 1998) .
The most widely used of these techniques is probably CSGE, because of its ease and speed of application and low cost. As with the other screening techniques, it does, however, suffer from the presence of false negative results. This is primarily due to the inability of a single electrophoresis condition to facilitate and maintain conformational changes in all heteroduplexes. While the use of multiple analysis conditions may overcome this problem, it is probably quicker to sequence all regions of the genes in those individuals who are negative upon initial screening. Newer screening techniques, such as those employing denaturing high performance liquid chromatography (DHPLC), may be able to detect all mutations, but require a considerable financial outlay to purchase the requisite equipment. CSGE therefore continues to be used for screening all OI patients for type I collagen gene mutations in this hospital. In individuals with types I, III and IV OI, mutations have been detected in one of the type I collagen genes in 50%, 66% and 80% of cases, respectively. Of the 36 out of 100 patients who were negative by CSGE screening, 9 have currently undergone full sequence analysis. In 4 of these cases, mutations not detected by CSGE were identified, but in the remaining 5 cases no type I collagen gene mutation could be identified. Thus, the deficiencies of the CSGE technique cannot be blamed for all the negative cases and it is likely that additional types of OI having a distinct genetic cause remain to be defined. To date 21 individuals with type V-VII OI have been analysed by CSGE, and all were negative for a type I collagen gene mutation. Of these, 5 individuals underwent full sequence analysis and all remained negative.
Diversity of type I collagen gene mutations
A multitude of different mutations have been described in the two type I collagen genes (COL1A1 and COL1A2) and are tabulated in the database of human collagen mutations (http://www.le.ac.uk/genetics/collagen) (Dalgleish, 1997). Mutations can involve both single nucleotide substitutions or base insertions and deletions, with missense mutations altering a glycine codon in the central exons of the genes encoding the protein region destined to form the characteristic collagen triple helix being most common. Replacement of either guanine (G) residue in the glycine codon (GGN) can theoretically result in replacement by eight different amino acids (serine, cysteine, alanine, valine, aspartic acid, glutamic acid, arginine and tryptophan). All possibilities have been described and all result in an OI phenotype, though the frequency with which the different mutations occur varies considerably, with serine replacement being most common and tryptophan replacement being exceedingly rare.
Other mutations include nonsense substitutions in arginine or glutamine codons, missense mutation in the carboxy propeptides, frame-shift and in-frame insertions/ deletions in the coding sequence, and a variety of intron mutations that affect splicing. Two features of these mutations are of note for their absence. First, no COL1A1 or COL1A2 mutation affecting exons encoding the amino propeptides of type I collagen molecules (exons 1-6) have been associated with OI, and secondly, nonsense substitutions and frame-shift mutations have not been observed in the COL1A2 gene.
Analysis of 101 patients in this hospital having type I collagen mutations revealed that 74 had point mutations resulting in glycine substitutions (Table 3 ). This included 49 of 55 patients with a mutation in the COL1A2 gene. The remaining 6 individuals with COL1A2 mutations had either splicing mutations or in-frame deletions/insertions. For COL1A1 mutations, only 25 of 54 patients had a glycine substitution. The reason for this lower incidence is primarily due to the presence of 19 individuals with nonsense or frame-shift mutations. In all cases this latter group exhibited mild disease and in most cases they presented with a type I OI phenotype. The other mutation types were associated with types I, III or IV OI.
Phenotype/genotype correlation
Many investigators have attempted to correlate triple helical glycine mutation type and location with phenotypic severity (Byers and Steiner, 1992) . This has proved to be an exceedingly difficult task, and there is no simple relationship that relates the type and position of a mutation in the helix to phenotype. Although some trends are apparent, such as phenotypic severity increasing with an amino to carboxy terminal orientation, with substitution by large and charged amino acids, and with COL1A1 versus COL1A2 mutations, there are many exceptions to these rules. There are a number of reasons to explain this variation. First, the collagen triple helix is not a uniform structure and exhibits regional differences in its stability and ability to accommodate mutations. This has led to the presentation of a regional model for OI severity, but full value of such a model awaits the identification of many more mutations to precisely define the different regions. Second, the intracellular consequences of a mutation are not constant, as different mutant messages or proteins can exhibit varying degrees of stability towards catabolism. This can influence the proportion of mutant collagen that is secreted by the osteoblast and also affect the synthesis of other gene products. Finally, gene mutations do not occur in isolation, but on a background of other factors that can influence bone strength. These factors may be due to genetic, nutritional or environmental variations between different individuals, and probably account for the fact that some commonly observed mutations can be associated with a variety of phenotypes.
Medical Treatment
The poor quality of the bone in OI patients is the major impediment to improving their quality of life, as it limits physical activity and impedes corrective orthopaedic surgery (Cinman, 2001; Engelbert et al., 1998; . Thus a medical means of improving bone strength would be of considerable value. Several treatments have been tried to therapeutically augment bone with varying success (Byers, 2000) . The greatest potential currently resides in bisphosphonate therapy (Fleisch, 1998) . Once in blood, bisphosphonates avidly bind to the hydroxyapatite crystals of bone and act as anti-resorptive agents by disrupting osteoclast action. In so doing they can prevent the loss of both trabecular and cortical bone and result in an increased bone mass compared to that otherwise expected in the OI patient.
Pamidronate therapy
This hospital has been involved in a clinical trial using cyclic intravenous pamidronate administration to treat children with OI (Glorieux et al., 1998; Plotkin et al., 2000; Rauch et al., 2002 Rauch et al., , 2003a Zeitlin et al., 2003b) . Bisphosphonate treatment increased bone mineral density by increasing cortical bone width and the number of trabeculae present (Figure 2 ). As a consequence fracture incidence decreased. Perhaps more importantly to the more severely affected patients, the chronic bone pain that they experience subsided, permitting increased mobility and improvement in muscle strength. An increase in the rate of growth was also noted in those patients who were of diminished stature. In all patients, quality of life was increased as individuals were able to perform physical tasks previously unattainable. For example, wheelchair bound patients were now able to ambulate with the aid of a walker.
Bisphosphonate therapy in children cannot be viewed as a totally beneficial process (Burr, 2002; Parfitt et al., 1996; Srivastava and Alon, 1999) . There are concerns with long term bisphosphonate use on the quality of bone that results when turnover is continuously suppressed, as such decreased remodelling may prevent repair of microdamage to the bone. As a consequence there may be limited benefit in continuing bisphosphonate therapy once growth has ceased and bone mineral density has plateaued. It is also possible that bisphosphonate therapy could impair the bone modelling process associated with fracture healing or surgical osteotomy. However, at present the benefits of bisphosphonate therapy by far outweigh its deficits.
Future directions
Bisphosphonate therapy is not a cure for OI, and while it improves bone strength by increasing the quantity of bone, it does not improve its quality as the gene defect is still present. It does, however, have the benefit of being applicable to all forms of OI, as it affects a common conse- quence of the disease not the gene mutation itself. Such disease-specific intervention will await the advent of effective and acceptable gene therapy (Forlino and Marini, 2000; Niyibizi et al., 2002) .
Conclusion
OI is a heterogeneous disorder with a broad spectrum of clinical and genetic diversity. The clinical phenotype is a consequence of both the genetic diversity and non-genomic factors. The genetic diversity includes a multitude of different mutations in the genes for type I collagen, but is not confined to mutations in these genes. Irrespective of the genetic origin, the consequence is abnormal bone formation resulting in low bone mass and an increased risk of fracture. Identification and classification of OI is based on clinical and histological changes resulting from the perturbations in bone structure and are currently independent of the genetic origin. Current medical treatment with bisphosphonates aims to improve these perturbations in bone function and is independent of both phenotype and genotype.
